We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+102.44%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$187M
AUM Growth
+$85.3M
Cap. Flow
+$31.5M
Cap. Flow %
16.85%
Top 10 Hldgs %
57.79%
Holding
64
New
29
Increased
5
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$13.7M
2
SION
Sionna Therapeutics
SION
+$6.85M
3
DVAX
Dynavax Technologies
DVAX
+$5.79M
4
DFTX
Definium Therapeutics
DFTX
+$5.26M
5
AXSM icon
Axsome Therapeutics
AXSM
+$5.23M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$7.99M
2
ETNB
89bio
ETNB
+$5.65M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$5.39M
4
BBIO icon
BridgeBio Pharma
BBIO
+$4.6M
5
SMMT icon
Summit Therapeutics
SMMT
+$4.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IQV icon
51
IQVIA
IQV
$34.4B
– –
-19,114
Closed -$3.63M
JAZZ icon
52
Jazz Pharmaceuticals
JAZZ
$15.5B
– –
-40,893
Closed -$5.39M
KROS icon
53
Keros Therapeutics
KROS
$211M
– –
-95,083
Closed -$1.5M
NKTR icon
54
Nektar Therapeutics
NKTR
$2.31B
– –
-51,270
Closed -$2.92M
PTGX icon
55
Protagonist Therapeutics
PTGX
$9.06B
– –
-20,358
Closed -$1.35M
QURE icon
56
uniQure
QURE
$2.77B
– –
-33,175
Closed -$1.94M
RAPT
57
DELISTED
RAPT Therapeutics
RAPT
– –
-34,449
Closed -$888K
REGN icon
58
Regeneron Pharmaceuticals
REGN
$70.9B
– –
-6,401
Closed -$3.6M
SMMT icon
59
Summit Therapeutics
SMMT
$10.7B
– –
-197,253
Closed -$4.08M
SNY icon
60
Sanofi
SNY
$107B
– –
-50,407
Closed -$2.38M
SRRK icon
61
Scholar Rock
SRRK
$6.33B
– –
-39,521
Closed -$1.47M
VIR icon
62
Vir Biotechnology
VIR
$1.59B
– –
-150,312
Closed -$858K
TECX
63
Tectonic Therapeutic
TECX
$615M
– –
-119,286
Closed -$1.87M
BCAX
64
Bicara Therapeutics
BCAX
$1.82B
– –
-175,902
Closed -$2.78M
1 2
3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Superstring Capital Management held 64 positions worth $187M, up 84% from $102M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Superstring Capital Management deployed $31.5M of net new capital in Q4 2025, opening 29 new positions and adding to 5 existing holdings. Its largest new stake was Sionna Therapeutics: 180,593 shares worth $7.43M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $7.99M trimmed.

  • Superstring Capital Management's largest Q4 2025 buy was Sionna Therapeutics: 180,593 shares worth $7.43M.
  • Superstring Capital Management added most to UroGen Pharma in Q4 2025, an estimated $13.7M increase.
  • Superstring Capital Management's biggest Q4 2025 reduction was Terns Pharmaceuticals, cutting an estimated $7.99M.
  • Superstring Capital Management fully exited 89bio in Q4 2025, selling an estimated $5.65M.
  • Superstring Capital Management's ten largest holdings make up 58% of its $187M portfolio in Q4 2025.
  • Superstring Capital Management opened 29 new positions and closed 19 in Q4 2025.
  • Superstring Capital Management's portfolio value rose 84% quarter-over-quarter to $187M.

Based on Superstring Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.